Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

The Lancet Diabetes & Endocrinology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles